Help | Scores |Exit
Fragmin | Magnex | Solu Medrol
Ramipril Drug Name:  
A|B|C|D|E|F|G|H|I|K|L|M|N|O|P|Q|R|S|T|V|Z
Indications
Dosages
Interactions
Precautions
Contraindications
Adverse Reactions
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interactions:

Allopurinol

  • Adverse Effect: hypersensitivity reactions (Stevens-Johnson syndrome, skin eruptions)  
  • Clinical Management: If these drugs are used concurrently, monitor for hypersensitivity reactions.

    Amiloride

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Aspirin

  • Adverse Effect: decreased captopril effectiveness  
  • Clinical Management: Although studies have suggested an interaction between ACE inhibitors and aspirin, the clinician should weigh the benefits against the risks of combining these two agents.

    Bumetanide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Celecoxib

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Chlorthalidone

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of Ramipril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Clopamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of Ramipril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Diclofenac Preps

    .
  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Erythropoietin

  • Adverse Effect: higher maintenance doses of erythropoietin to maintain the target hematocrit  
  • Clinical Management: Monitor patients receiving angiotensin converting enzyme inhibitors for erythropoietin efficacy. When given concomitantly, doses of erythropoietin may be higher than expected.

    Flurbiprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

     Frusemide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Ibuprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Indapamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Indomethacin

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Ketoprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Ketorolac

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Lithium

  • Adverse Effect: Lithium toxicity (weakness, tremor, excessive thirst, confusion) and/or nephrotoxicity  
  • Clinical Management: The combination of lithium and Ramipril should be avoided if possible, though the choice of an alternative antihypertensive agent that does not interact with lithium is limited. If lithium and Ramipril are used concurrently, serum lithium levels should be closely monitored and the patient followed for any symptoms of lithium toxicity.

     Mefenamic Acid

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Meloxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Nabumetone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Naproxen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Nimesulide

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Oxyphenbutazone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Paracetamol

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

     Phenacetin

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Phenylbutazone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Piroxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Spironolactone

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Tenoxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Xipamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.
  • Ranitidine
    Respiratory Syncytial Virus
    Ribavirin
    Rifampin
    Rabeprazole sodium
    Rabies Vaccine
    Raloxifene
    Ramipril
    Repaglinide
    Reserpine
    Reviparin
    Ribaverin
    Rifampicin
    Risperidone
    Ritodrine
    Rofecoxib
    Roxatidine
    Roxithromycin
    Rtpa
    Rubella Vaccine
    Rutin
     
    Disclaimer